Dr Reddy's Laboratories today said the US health regulator USFDA has issued no observations after inspecting its formulations plant in Andhra Pradesh.
"The audit of our formulations Srikakulum Plant (SEZ) Unit II, Andhra Pradesh by the US FDA, has been completed today with zero observations," Dr Reddy's Laboratories said in a regulatory filing.
US Food and Drug Administration (USFDA) issues Form 483 observations to a company at the conclusion of an inspection to notify it of objectionable conditions at the facility.
Dr Reddy's Laboratories shares today ended 3.7 per cent down at Rs 2,427.30 apiece on BSE.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)